FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2494-2495 December 7, 2006 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: In a recent cross-sectional study, Berman et al. found that some patients who were treated with imatinib mesylate had hypophosphatemia, with low-normal serum calcium levels, elevated levels of parathyroid hormone, and low-normal bone turnover.¹ It is not clear what mechanism (or mechanisms) underlie these biochemical abnormalities. We have prospectively studied biochemical indexes of calcium metabolism in blood and urine samples obtained after an overnight fast from nine patients (six men and three women, with a mean [±SD] age of 46±10 years) who had the BCR-ABL mutation and were starting imatinib therapy (at a dose of 400 mg . . . [Full Text of this Article]

This article has been cited by other articles:

• O'Sullivan, S., Horne, A., Wattie, D., Porteous, F., Callon, K., Gamble, G., Ebeling, P., Browett, P., Grey, A. (2009). Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib. J. Clin. Endocrinol. Metab. 94: 1131-1136 [Abstract] [Full Text]  
• Jonsson, S., Olsson, B., Ohlsson, C., Lorentzon, M., Mellstrom, D., Wadenvik, H. (2008). Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. haematol 93: 1101-1103 [Full Text]  
• Fitter, S., Dewar, A. L., Kostakis, P., To, L. B., Hughes, T. P., Roberts, M. M., Lynch, K., Vernon-Roberts, B., Zannettino, A. C. W. (2008). Long-term imatinib therapy promotes bone formation in CML patients. Blood 111: 2538-2547 [Abstract] [Full Text]